Is Zepbound in shortage? On paper, no. October 2024 is when the FDA closed out the tirzepatide shortage, a decision it stood behind again that December, and the drug has stayed off the shortage list ever since. The reason people still ask is Zepbound in shortage is that an official listing and a stocked pharmacy shelf are different things, and local availability of a specific strength still varies.
Because the situation can change, verify it yourself rather than trusting any article, including this one. The FDA Drug Shortages database is searchable and authoritative, and "tirzepatide injection" is the entry to look for.
Is Zepbound in Shortage? Official Status Versus Local Stock
The FDA shortage list tracks whether the manufacturer can meet national demand. It does not track whether your pharmacy has 10 mg pens today.
Those two things came apart during 2025 and 2026. Drug substance supply improved, but individual pharmacies still reported gaps at particular strengths, and the higher maintenance doses were most affected. Injector device manufacturing, rather than the medicine itself, has been the more common constraint.
For a patient, that distinction is academic. What matters is whether the dose you need is obtainable this week.
What Changed When the Shortage Ended
The end of the official shortage had one consequence that caught many people out.
While a drug is listed as in shortage, compounding pharmacies may prepare copies of it under specific regulatory provisions. Once the shortage is resolved, that permission ends. Mass compounding of tirzepatide is no longer lawful, and compounded versions are limited to genuine patient-specific clinical need rather than as a routine cheaper alternative.
Anyone who moved to compounded tirzepatide during the shortage and assumed that route would remain open has had to find something else. Our compounded tirzepatide guide covers where that leaves things.
Your Options if a Dose Is Out
| Option | How fast | What it costs you | Main limitation |
|---|---|---|---|
| Call other pharmacies for the same strength | Same day | Nothing | Depends entirely on local allocation |
| Switch from pens to single-dose vials | Days, needs a new prescription | Similar or less | Requires drawing the dose with a syringe |
| Manufacturer direct self-pay vials | Days | Below list price, but no insurance applied | Bypasses coverage, so poor value with good insurance |
| Hold at your current strength | Immediate | Nothing | Prescriber decision, may slow progress |
| Mail order or independent pharmacy | Around a week | Similar | Not useful if you need a dose this week |
| Compounded tirzepatide | Varies | Varies | Now restricted to patient-specific clinical need |
If Your Dose Is Not Available
Call ahead rather than driving around. Pharmacies can check stock by strength over the phone, and a prescription sent to a store that has none simply sits there.
Ask about the other formats. Zepbound is supplied both as single-dose pens and as single-dose vials. Vials have frequently been easier to obtain than pens because the constraint has often been device manufacturing rather than the drug. This requires a prescription written for the vial presentation, and the vial is drawn up with a separate syringe.
Check the manufacturer's direct pharmacy. Self-pay vials sold direct by the manufacturer have often been available when retail pens were not, at prices well below list. This route bypasses insurance entirely, which is a disadvantage for anyone with coverage and an advantage for anyone without.
Try a different pharmacy type. Independent pharmacies and mail-order services often have different supply patterns from large chains.
Ask about a nearby strength. If 12.5 mg is unavailable but 10 mg is on the shelf, staying at 10 mg for another cycle is usually preferable to interrupting treatment. This is a prescriber decision, not one to make yourself.
What Not to Do
Do not stretch doses to make a pen last. Splitting or extending doses to cover a gap risks under-dosing and dosing errors, and the pens are not designed for it.
Do not buy tirzepatide from a research chemical vendor. Products sold this way are not prepared for human use, have no pharmacy oversight, and the concentration on the label is only as reliable as the seller. This is a genuinely different risk category from a pharmacy shortage.
Do not stop abruptly and assume nothing happens. Appetite returns and weight regain is common after stopping, so a supply gap is worth actively managing rather than waiting out.
If You Have to Pause
Missing one weekly dose is not an emergency. Tirzepatide has a half-life of around five days, so levels fall gradually rather than dropping off a cliff.
A longer gap is different. Gastrointestinal tolerance fades within a few weeks, and restarting at a full maintenance dose after an extended break can cause significant nausea. Prescribers often restart at a lower dose and re-titrate after a substantial interruption, which is inconvenient but safer.
Our missed tirzepatide dose guide covers the shorter gaps in detail.
How to Check for Yourself
- Search the FDA Drug Shortages database for "tirzepatide injection" and read the current entry.
- Call two or three local pharmacies and ask specifically about your strength, not the drug in general.
- Ask your prescriber about the vial presentation if pens are the sticking point.
- Compare the manufacturer's direct self-pay price against what your coverage actually delivers, since for some people without good coverage the direct route is both cheaper and more reliable.
For related reading, see the Zepbound guide, the cost breakdown without insurance and how to get Zepbound.
Frequently Asked Questions
Does the FDA still list Zepbound as short?
No. Tirzepatide came off the shortage list in October 2024, the agency confirmed that call two months later, and nothing has put it back on since. What people run into now is a particular strength being unavailable at a particular counter, which is a stocking problem in one shop rather than a national one.
Why can my pharmacy not get my dose then?
Local stock depends on ordering patterns, allocation and which strengths a particular store keeps. The higher maintenance doses have been the most affected, and injector pen supply has been a tighter constraint than the medicine itself. Calling several pharmacies usually resolves it faster than waiting.
Can I still get compounded tirzepatide?
Only in limited circumstances. Mass compounding was permitted while the drug was listed in shortage, and that permission ended when the shortage was resolved. Compounded tirzepatide is now restricted to specific patient-level clinical need rather than being a routine lower-cost route.
Should I ask for vials instead of pens?
It is often the faster route. Where supply has been tight, the bottleneck has usually been building injector devices rather than making the medicine, which leaves vials on the shelf while pens are not. The catch is administrative and practical: the prescription has to specify the vial presentation, and you draw each dose up yourself with a syringe.
What happens if I miss a few weeks of Zepbound?
Appetite returns as levels fall, and weight regain is common. Gastrointestinal tolerance also fades within a few weeks, so restarting at a full maintenance dose after a long gap can cause significant nausea. Prescribers often restart lower and re-titrate after an extended interruption.
